MusclePharm Corporation (MSLP)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MusclePharm Corporation (MSLP) with AI Score 38/100 (Weak). MusclePharm Corporation develops, manufactures, and distributes sports nutrition products and nutritional supplements. Market cap: 0, Sector: Consumer defensive.
Last analyzed: Mar 16, 2026MusclePharm Corporation (MSLP) Consumer Business Overview
MusclePharm Corporation, operating in the sports nutrition sector, offers a range of performance and essential supplements targeting athletes and fitness enthusiasts. The company's product portfolio includes protein powders, bars, and energy beverages, marketed under the MusclePharm and FitMiss brands. Currently undergoing reorganization after filing for Chapter 11 bankruptcy, the company faces challenges in a competitive market.
Investment Thesis
MusclePharm Corporation presents a complex investment case, especially given its Chapter 11 bankruptcy filing in December 2022. The company's negative profit margin of -25.7% and a low gross margin of 10.7% highlight significant financial challenges. A potential value driver lies in successful restructuring and a return to profitability, contingent on effectively managing debt and streamlining operations. Growth catalysts include innovation in product offerings and expansion into new markets, though these are speculative at this stage. The company's beta of -0.05 suggests a low correlation with the market, which could be seen as a defensive characteristic. However, the lack of dividends provides no immediate return for investors. Investors should closely monitor the bankruptcy proceedings and the company's ability to regain financial stability.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross margin of 10.7% indicates challenges in profitability and cost management.
- Negative profit margin of -25.7% reflects significant losses and operational inefficiencies.
- Filed for Chapter 11 bankruptcy in December 2022, indicating severe financial distress.
- Beta of -0.05 suggests a low correlation with the overall market, potentially offering some downside protection.
- No dividend yield, providing no immediate income for investors.
Competitors & Peers
Strengths
- Established brand recognition in the sports nutrition market.
- Diverse product portfolio catering to various fitness needs.
- Distribution network through online and physical channels.
- Formulation expertise in developing effective supplements.
Weaknesses
- Recent Chapter 11 bankruptcy filing.
- Negative profit margin and low gross margin.
- Limited financial resources for marketing and product development.
- Dependence on a limited number of key products.
Catalysts
- Ongoing: Restructuring efforts to emerge from Chapter 11 bankruptcy.
- Upcoming: Potential for new product launches in the sports nutrition market.
- Ongoing: Cost optimization initiatives to improve profitability.
- Upcoming: Strategic partnerships to expand distribution channels.
Risks
- Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.
- Potential: Intense competition in the sports nutrition market.
- Potential: Changing consumer preferences and trends.
- Ongoing: Limited financial resources for marketing and product development.
- Potential: Regulatory scrutiny and compliance requirements.
Growth Opportunities
- Product Innovation: Developing new and innovative sports nutrition products, including plant-based and personalized nutrition options, could drive growth. The market for plant-based protein is expanding rapidly, with a projected market size of $14.5 billion by 2027. MusclePharm could capitalize on this trend by introducing new product lines targeting vegan and vegetarian athletes. Timeline: 1-2 years.
- E-commerce Expansion: Enhancing its online presence and direct-to-consumer sales channels can improve profitability and reach a broader customer base. The global e-commerce market is expected to reach $6.2 trillion in 2024. By investing in its online platform and digital marketing, MusclePharm can increase its sales and brand visibility. Timeline: Ongoing.
- International Market Penetration: Expanding into new international markets, particularly in Asia and Europe, offers significant growth potential. The global sports nutrition market is projected to reach $37.27 billion by 2028. Entering these markets requires adapting product formulations and marketing strategies to local preferences. Timeline: 2-3 years.
- Strategic Partnerships: Forming strategic partnerships with gyms, fitness centers, and sports teams can enhance brand visibility and drive sales. Collaborating with influencers and athletes can also boost brand awareness and credibility. These partnerships can provide access to new customer segments and distribution channels. Timeline: Ongoing.
- Cost Optimization: Implementing cost-cutting measures and streamlining operations can improve profitability and financial stability. This includes optimizing the supply chain, reducing overhead expenses, and improving production efficiency. Successful cost optimization is crucial for MusclePharm to emerge from bankruptcy and return to sustainable growth. Timeline: Ongoing.
Opportunities
- Expanding into new international markets.
- Developing innovative plant-based and personalized nutrition products.
- Enhancing e-commerce presence and direct-to-consumer sales.
- Forming strategic partnerships with gyms and fitness centers.
Threats
- Intense competition from established players in the sports nutrition market.
- Changing consumer preferences and trends.
- Regulatory scrutiny and compliance requirements.
- Economic downturn affecting consumer spending.
Competitive Advantages
- Brand recognition, particularly within the MusclePharm brand.
- Established product portfolio across various supplement categories.
- Distribution network through online and physical retailers.
- Formulation expertise in sports nutrition.
About MSLP
MusclePharm Corporation, founded in 2006, develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements. The company's initial vision was to provide athletes with safe and effective supplements to enhance performance. Over the years, MusclePharm expanded its product line to include a wide array of offerings, such as performance powders, capsules, tablets, gels, and ready-to-eat snacks. Key brands include MusclePharm, known for its Combat Protein Powder and Combat Crunch protein bars, and FitMiss, a line of sports nutrition products formulated primarily for women. These products are designed to support weight management, lean muscle mass, and overall health and wellness. The company also offers functional energy beverages under the Combat Energy and FitMiss Energy brands. MusclePharm sells its products to athletes and fitness enthusiasts through various channels, including online retailers, specialty stores, and gyms. In December 2022, MusclePharm filed for Chapter 11 bankruptcy, signaling a significant challenge in its operational history. The company is based in Las Vegas, Nevada, and operates both domestically and internationally.
What They Do
- Develops and manufactures sports nutrition products.
- Markets and distributes nutritional supplements.
- Offers performance powders, capsules, and tablets.
- Provides ready-to-eat snacks and gels.
- Formulates products for both men and women.
- Sells products to athletes and fitness enthusiasts.
- Offers functional energy beverages.
Business Model
- Develops and manufactures sports nutrition products and supplements.
- Markets products through online retailers, specialty stores, and gyms.
- Generates revenue through the sale of its MusclePharm and FitMiss branded products.
- Focuses on athletes and fitness enthusiasts as its primary customer base.
Industry Context
MusclePharm operates within the competitive sports nutrition industry, which is characterized by evolving consumer preferences and a focus on health and wellness. The market includes major players and smaller niche brands, all vying for market share. Trends include a growing demand for plant-based protein and personalized nutrition. MusclePharm's bankruptcy reflects challenges in adapting to these trends and managing operational costs. Competitors include companies like BVNNF (BioVaxys Technology Corp.) and HBIS (Hoth Therapeutics Inc.), each with different market focuses. The industry is driven by innovation in product formulation and marketing strategies that resonate with health-conscious consumers.
Key Customers
- Athletes seeking performance enhancement.
- Fitness enthusiasts focused on health and wellness.
- Individuals looking for weight management solutions.
- Consumers interested in lean muscle mass development.
Financials
Chart & Info
MusclePharm Corporation (MSLP) stock price: Price data unavailable
Latest News
No recent news available for MSLP.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MSLP.
Price Targets
Wall Street price target analysis for MSLP.
MoonshotScore
What does this score mean?
The MoonshotScore rates MSLP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ryan Charles Drexler
CEO
Ryan Charles Drexler serves as the CEO of MusclePharm Corporation, managing a team of 21 employees. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Therefore, a comprehensive background cannot be provided at this time. Further research would be required to ascertain his specific qualifications and experience prior to joining MusclePharm.
Track Record: Due to the limited information available, it is not possible to provide a detailed track record of Ryan Charles Drexler's achievements, strategic decisions, or company milestones under his leadership. His tenure and specific contributions to MusclePharm's performance remain unknown based on the provided data.
MSLP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MusclePharm may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited financial reporting and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is considered more speculative due to the increased risk associated with less transparent and potentially financially distressed companies. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in MusclePharm.
- Lower liquidity can lead to difficulties in buying or selling shares.
- Increased price volatility can result in significant losses.
- Potential for delisting or further financial distress.
- Higher risk of fraud or manipulation compared to exchange-listed stocks.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their experience.
- Evaluate the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Analyze the company's debt and cash flow situation.
- Monitor the company's news and press releases for any updates.
- Consult with a financial advisor before investing.
- Established brand recognition in the sports nutrition market.
- Existing product portfolio and distribution network.
- Continued operations despite Chapter 11 bankruptcy.
- Presence of a CEO and management team.
- Historical operating history since 2006.
Common Questions About MSLP
What does MusclePharm Corporation do?
MusclePharm Corporation develops, manufactures, markets, and distributes a range of sports nutrition products and nutritional supplements. Its product portfolio includes performance powders, capsules, tablets, gels, and ready-to-eat snacks, marketed under the MusclePharm and FitMiss brands. These products are designed for athletes and fitness enthusiasts, focusing on performance enhancement, weight management, and overall health and wellness. The company sells its products through online retailers, specialty stores, and gyms, targeting both domestic and international markets. Currently, the company is undergoing reorganization after filing for Chapter 11 bankruptcy in December 2022.
What do analysts say about MSLP stock?
There is currently no available analyst consensus on MusclePharm Corporation (MSLP) due to its OTC listing and recent Chapter 11 bankruptcy filing. Key valuation metrics such as price-to-earnings ratio are not meaningful given the company's negative profitability. Growth considerations are speculative at this stage, contingent on successful restructuring and a return to profitability. Investors should conduct their own thorough analysis and consider the high-risk nature of this investment. The stock's performance will likely depend on the company's ability to manage its debt, streamline operations, and regain financial stability.
What are the main risks for MSLP?
The primary risk for MusclePharm Corporation is its ongoing Chapter 11 bankruptcy proceedings, which could potentially lead to liquidation. Additional risks include intense competition in the sports nutrition market, changing consumer preferences, and limited financial resources for marketing and product development. Regulatory scrutiny and compliance requirements also pose challenges. The company's negative profit margin and low gross margin highlight significant financial vulnerabilities. Investors should be aware of the high-risk nature of this investment and the potential for significant losses.
What are the key factors to evaluate for MSLP?
MusclePharm Corporation (MSLP) currently holds an AI score of 38/100, indicating low score. Key strength: Established brand recognition in the sports nutrition market.. Primary risk to monitor: Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.. This is not financial advice.
How frequently does MSLP data refresh on this page?
MSLP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MSLP's recent stock price performance?
Recent price movement in MusclePharm Corporation (MSLP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established brand recognition in the sports nutrition market.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MSLP overvalued or undervalued right now?
Determining whether MusclePharm Corporation (MSLP) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MSLP?
Before investing in MusclePharm Corporation (MSLP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- OTC market carries higher risks than exchange-listed stocks.
- Financial data may be outdated or incomplete due to bankruptcy proceedings.